Company: FTII
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001641172-25-025250
Chunk: 65

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 65
---
 share of Purchaser Common Stock, and instead will at the Acquisition Merger Effective Time be converted
into the right to receive from the Purchaser, in cash, an amount per share calculated in accordance with such stockholder’s redemption
rights. As of the Merger Effective Time, all such Redemption Shares shall no longer be outstanding and shall automatically be cancelled
and retired and shall cease to exist, and each holder of a Redemption Share (or related certificate or book-entry shares) shall cease
to have any rights with respect thereto, except the right to receive the cash payments from Purchaser referred to in the immediately
preceding sentence.

12

The
foregoing is only a summary of the terms of the Amended Merger Agreement, readers are referred to the actual Amended Merger Agreement
for its fully meaning and legal effect. A copy of the Amended Merger Agreement is filed with this Current Report as Exhibit 2.1 and is
incorporated herein by reference, and the foregoing description of the Merger Agreement is qualified in its entirety by reference thereto.

Pursuant
to the Amended Merger Agreement, Longevity shall, prior to the closing of the Reorganization Merger, consummate the Target Acquisitions
upon the terms and subject to conditions set forth therein and pursuant to the Target Acquisition Agreements. The Target Acquisitions
are the acquisitions by Longevity of each of Cerevast Medical, Inc. and Aegeria Soft Tissue, LLC (“Aegeria”) pursuant to
each of the Cerevast Acquisition Agreement and the Aegeria Acquisition Agreement, each in accordance with the respective terms thereof.

On
August 12, 2025, the Company consented (the “Approval of Waiver”) to Longevity entering into a waiver agreement with Aegeria
(the “Waiver Agreement”) to remove the restriction contained in the Aegeria Acquisition Agreement that prohibited Aegeria
from soliciting, negotiating, entering into, or otherwise facilitating an acquisition proposal or alternative transaction.

The
foregoing description of the Approval of Waiver and the Waiver Agreement does not purport to be complete and is qualified in its entirety
by the terms and conditions of the Approval of Waiver and the Waiver Agreement and any related agreements. A copy of the Approval of
Waiver and the Waiver Agreement are filed with this Current Report as Exhibits 10.1 and 10.2, respectively and are incorporated herein
by reference.

August
14